4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q3 EPS of ($1.01), in-line with the analyst estimate of ($1.01).

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.